RxDoctor Payments Data

Rasa Miller, MD

Family Medicine · Mc Calla, ALNPI 1982672952

Payments from drug & device makers

$4,621in general payments, 2019–2025

Across 305 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$644
  • Pfizer$545
  • GSK$526
  • Johnson & Johnson$425
  • Amgen$224
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,621100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,621 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$28,083
Medicare patients
115
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$111,295
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog57$67,004
JardianceEmpagliflozin55$61,479
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$57,331
EliquisApixaban70$55,229
Tresiba Flextouch U-200Insulin Degludec15$30,636
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$27,670
LinzessLinaclotide36$24,128
XareltoRivaroxaban20$21,302
Spiriva RespimatTiotropium Bromide34$17,587
KerendiaFinerenone23$17,047
JanuviaSitagliptin Phosphate26$14,600
FarxigaDapagliflozin Propanediol20$12,935
GemtesaVibegron15$6,459
Spiriva HandihalerTiotropium Bromide12$6,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,054$111,29582 claims
Boehringer IngelheimJardiance, Spiriva Respimat$139$79,06689 claims
GSKTrelegy Ellipta$526$57,33187 claims
PfizerEliquis$545$55,22970 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$117$44,08473 claims
AbbVieLinzess$644$24,12836 claims
Johnson & JohnsonXarelto$425$21,30220 claims
MerckJanuvia$131$14,60026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Mc Calla

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →